Borrowed antibodies: The characteristics and roles of immune globulins

Hospital Pharmacy

Volumn 35, Issue 4, 2000, Pages 393-404

  Grabenstein, John D ^a  

^a US Army Medical Command   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITOXIN; ARCITUMOMAB TC 99M; BAYGAM; BAYRAB; BAYTET; CAPROMAB PENDETIDE IN 111; CYTOMEGALOVIRUS ANTIBODY; DIGIBAND; HEPATITIS B ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MEASLES VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; MYOSIN ANTIBODY IN 111; NOFETUMOMAB; OKT 3; PALIVIZUMAB; PANGLOBULIN; POLYCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RHESUS D ANTIBODY; RITUXIMAB; THYMOCYTE ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; VERLUMA;

ACTIVE IMMUNIZATION; ANTIBODY PRODUCTION; B CELL LEUKEMIA; BACKACHE; BONE MARROW TRANSPLANTATION; BOTULISM; BREAST CANCER; CANCER DIAGNOSIS; CHICKENPOX; CLINICAL TRIAL; CONTINUING EDUCATION; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DIPHTHERIA; GRAFT VERSUS HOST REACTION; HEADACHE; HEART MUSCLE INJURY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMEDIATE TYPE HYPERSENSITIVITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; NONHODGKIN LYMPHOMA; PASSIVE IMMUNIZATION; PHARMACIST; PRURITUS; RABIES; RASH; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHEUMATOID ARTHRITIS; TETANUS;

EID: 0034039879     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870003500403     Document Type: Review

References (61)

1. Parish HJ. A History of Immunizations. Edinburgh and London: Livingstone; 1965.
2. Stiehm ER. Intravenous immunoglobulins as therapeutic agents. Ann Intern Med. 1987;107:367-92.
3. Stiehm ER. Human gamma globulins as therapeutic agents. Adv Pediatr. 1988; 35:1-72.
4. Hambleton P, Carman JA, Melling J. Anthrax: The disease in relation to vaccines. Vaccine. 1984; 2:125-32.
5. Stiehm ER. Standard and special human immune serum globulins as therapeutic agents. Pediatrics. 1979;63:301-19.
6. Grabenstein JD. ImmunoFacts: Vaccines and Immunologic Drugs. 17th rev. Saint Louis: Facts & Comparisons, Inc.; February 2000.
7. Thalley BS, Carroll SB. Rattlesnake and scorpion antivenoms from the egg yolks of immunized hens. Biotechnology. 1990;8: 934-8.
8. Doman CE. Landmarks and pioneers in the control of diphtheria. Can J Public Health. 1973;64:317-36.
9. Lévy FM. A corner of history: The fiftieth anniversary of diphtheria and tetanus immunization. Prevent Med. 1975;4: 226-37.
10. English PC. Diphtheria and theories of infectious disease: Centennial appreciation of the critical role of diphtheria in the history of medicine. Pediatrics. 1985;76:1-9.
11. Hróbjartsson A, Gotzsche PC, Gluud C. The controlled clinical trial turns 100 years: Fibiger's trial of serum treatment of diphtheria. BMJ. 1998;317:1243-5.
12. English PC. Therapeutic strategies to combat pneumococcal disease: Repeated failure of physicians to adopt pneumococcal vaccine, 1900-1945. Perspect Biol Med. 1987;30:170-85.
13. Watson DA, Musher DM, Jacobson JW, et al. A brief history of the pneumococcus in biomedical research: A panoply of scientific discovery. Clin Infect Dis. 1993;17:913-24.
14. Janeway CA. Blood and blood derivatives: A new public health field. Am J Public Health. 1946;36:1-14.
15. Grabenstein JD. Immunoantidotes: 1. Antivenins. Hosp Pharm. 1992;27:427-31, 435,449.
16. Grabenstein JD. Immunoantidotes: 2. One hundred years of antitoxins. Hosp Pharm. 1992;27:637-40,645-6,664.
17. Grabenstein JD. Immunoantidotes: 3. Antidigoxin, antichemical, and other antibodies. Hosp Pharm. 1992;27:786, 789-91,795-6.
18. Bloch AB, Orenstein WA, Stetler HC, et al. Health impact of measles vaccination in the United States. Pediatrics. 1985;76:524-32.
19. Grabenstein JD. Obsolete immunologic drugs, Part 1. Hosp Pharm. 1997;32: 348-50,353-4,357-8.
20. Grabenstein JD. Obsolete immunologic drugs, Part 2. Hosp Pharm. 1997; 32:492,501-3,507-8,511.
21. Freda VJ, Gorman JG, Pollack W, Bowe E. Prevention of Rh hemolytic disease: Ten years' experience with Rh immune globulin. N Engl J Med. 1975; 292:1014-6.
22. o(D) immune globulin. Hosp Pharm. 1992;27:981-2,985-7.
23. Grabenstein JD. Isoantibodies: 2. Comparison of antilymphocyte antibodies. Hosp Pharm. 1993;28:42,45-9.
24. Kao NL. How immunoglobulins were named [letter]. Ann Intern Med. 1992;117:445.
25. Stokes J Jr., Neefe JR. The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA. 1945;127:144-5.
26. Dwyer JM. Thirty years of supplying the missing link: History of gamma globulin therapy for immunodeficient states. Am J Med. 1984;76:46-52.
27. McCue JP, Hein RH, Tenold R. Three generations of immunoglobulin G preparations for clinical use. Rev Infect Dis. 1986;8(suppl 4):S374-81.
28. Good RA, Lorenz E. Historic aspects of intravenous immunoglobulin therapy. Cancer. 1991;68:1415-21.
29. Janeway CA, Merler E, Rosen FS, et al. Intravenous gamma globulin: Metabolism of gamma globulin fragments in normal and agammaglobulinemic persons. N Engl J Med. 1968;278:919-23.
30. Grabenstein JD. The safety and hazards of blood-derived drugs. Am J Health-Syst Pharm. 1995;52:2448-52.
31. Grabenstein JD. Milestones in immunologie history: Antiquity to 1919. Hosp Pharm. 1994;29:477-8,480-3.
32. Bresee JS, Mast EE, Coleman PJ, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin: A cohort study. JAMA. 1996;276:1563-7.
33. Centers for Disease Control and Prevention. Outbreak of hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993-June 1994. MMWR. 1994;43:505-9.
34. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med. 1994;331:1607-11.
35. Power JP, Lawlor E, Davidson F, et al. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet. 1995;345:1211-13.
36. Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet. 1995;345:1209-11.
37. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med. 1994;331:1649-50.
38. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722-8.
39. Knapp MJ, Colburn PA. Clinical uses of intravenous immune globulins. Clin Pharm. 1990;9:2509-29.
40. Wordell CJ. Use of intravenous immune globulin therapy: An overview. DICP-Ann Pharmacother. 1991;25:805-17.
41. American Society of Hospital Pharmacists. ASHP therapeutic guidelines for intravenous immune globulin. Clin Pharm. 1992;11:117-36.
42. Thürmann P, Harder S. Criteria for the appropriate drug utilisation of immunoglobulin. Pharmacoeconomics. 1996;9:417-29.
43. Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: A meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995;96:1057-61.
44. National institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991;325:73-80.
45. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323:705-12.
46. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for The American Society of Hematology. Blood. 1996;88:3-40.
47. American Society of Hematology. Diagnosis and treatment of idiopathic thrombocytopenic purpura: Recommendations of the American Society of Hematology. Ann Intern Med. 1997;126:319-26.
48. Ratko TA, Burnett DA, Foulke GE, et al. Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA. 1995;273:1865-70.
49. Dalakas M. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med. 1997;126:721-30.
50. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol. 1997;100:151-7.
51. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet. 1993;341:789-90.
52. Lucas GS, Jobbins K, Bloom AL. Intravenous immunoglobulin and blood-group antibodies [letter]. Lancet. 1987;ii:742.
53. Sekul EA, Cupler EJ, Dalakos MC. Aseptic meningitis associated with high-dose IV immunoglobulin therapy. Ann Intern Med. 1994;121:259-62.
54. Scribner CL, Kapit RM, Phillips ET, et al. Aseptic meningitis and IV immunoglobulin therapy. Ann Intern Med. 1994;121:305-6.
55. Centers for Disease Control and Prevention. Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998. MMWR. 1999;48:518-21.
56. American Academy of Pediatrics. Recommended timing of routine measles immunization for children who have recently received immune globulin preparations. Pediatrics. 1994;93:682-5.
57. Advisory Committee on Immunization Practices. General recommendations on immunization. MMWR. 1994;43(RR-1): 1-38.
58. Grabenstein JD. Vaccines and antibodies in relation to pregnancy and lactation. Hosp Pharm. 1999;34:949-52,955-6,959-60.
59. Vaswani SK, Hamilton RG. Humanized antibodies as potential therapeutic drugs. Ann Allergy Asthma Immunol. 1998; 81:105-19.
60. Decker EL, Gouveia WA. Managing the shortage of intravenous immune globulin. Am J Health-Syst Pharm. 1998;55: 2090,2093.
61. Centers for Disease Control and Prevention. Availability of immune globulin intravenous for treatment of immune deficient patients-United States, 1997-1999. MMWR. 1999;48:159-62.